KENYA – PHASE Scientific’s INDICAID COVID-19 Rapid Antigen Test has received Emergency Use Authorization from the Ministry of Health (MOH) of the Republic of Kenya.
The authorization enables the test to be used in Kenya for the identification of COVID-19 cases, facilitating early isolation, diagnosis and treatment of patients.
The INDICAID COVID-19 Rapid Antigen Test is a lateral flow immunoassay designed for qualitative detection of SARS-CoV-2 antigens.
Unlike other testing methods that use nasopharyngeal swab specimens, INDICAID uses nasal swab specimens to provide fast results within 20 minutes without need of any special equipment or facilities.
INDICAID has been validated in the world’s largest clinical trial for a product of its kind, results from which have been published in Microbiology Spectrum on 4 August 2021.
“The authorization of INDICAID™ from various countries indicates our technology and quality are well-recognized globally,” says Dr. Ricky Chiu Yin-to, Founder and CEO of PHASE Scientific.
Dr. Chiu has also mentioned that Kenya is the first market in Africa the Company enters, and that it will continue expanding to other African countries to help combat COVID-19.
INDICAID COVID-19 Rapid Antigen Test has received Emergency Use Authorization from the US Food & Drug Administration (FDA) and the European CE Mark.
The kit has been widely adopted in COVID-19 testing centers, hospitals, government and private corporations, supermarkets, hotels and schools in Hong Kong and overseas.
INDICAID is currently available in 33 countries, and is the best-selling rapid test kit in Hong Kong.
Yesterday, 346 people tested positive for COVID-19 in Kenya, from a sample size of 3,553. The positivity rate in the East African nation is now at 9.7%. Total confirmed positive cases are now 235,298 and cumulative tests so far conducted are 2,367,077.
At the same time, 10 patients succumbed to the disease, all of them being late deaths reported after conducting facility record audits on diverse dates in August 2021. This now pushes the cumulative fatalities to 4,720.
As of August 29th, 2021, a total of 2,752,266 vaccines had so far been administered across the country. Of these, total first doses are 1,949,340 while second doses are 802,926.
The uptake of the second dose among those who received their first dose is at 41.2% with the majority being males at 55% while females are at 45%. Proportion of adults fully vaccinated is 2.95%.
Speaking during the daily national Covid-19 briefing, Cabinet Secretary of Health, Mr. Mutahi Kagwe urged all citizens to get vaccinated at the Ministry of Health designated vaccination approved sites.
Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE
